Pharmacotherapy in idiopathic pulmonary fibrosis

Gaurav Acharya¹, Sunil Arya², Shivani Badal³, Dewesh Kumar⁴*, Saurabh Samdariya⁵

INTRODUCTION

Idiopathic pulmonary fibrosis (IPF) or cryptogenic fibrosing alveolitis is a form of chronic, progressive interstitial lung disease causing scarring of lung tissue and usually affect adults. Treatment is usually aimed at controlling inflammation and thus slowing the process of fibrosis. With only few patients responding to treatment and the disease being ultimately fatal with poor progression, the underlying lesion was considered to be fibrotic rather than inflammatory. Fibrotic foci, deposition of collagen, and lack of inflammatory cells are a predominant finding. Pirfenidone and N-acetyl cysteine are the only effective pharmacotherapy available till date. Interim results of PANTHER Trial clearly indicate more risk with triple therapy. However, in Indian patients, trial of steroid therapy may be tried when there is doubt of chronic hypersensitivity pneumonitis. BIBF 1120 has also shown positive results in Phase II clinical trial and shows a positive response in deteriorating lung function. Supplemental oxygen, education of patient, pulmonary rehabilitation, and Streptococcus pneumoniae and influenza vaccine are the most important supportive care. Pulmonary rehabilitation should be used as a treatment in the majority of patients.

Keywords: Idiopathic pulmonary fibrosis, Pirfenidone, N-acetyl cysteine, Interstitial lung disease
PHARMACOLOGICAL INTERVENTIONS

**Pirfenidone**

This novel drug is the latest area of research as anti-fibrotic agent. Pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) inhibits transforming growth factor beta stimulated collagen deposition, causes a reduction in extracellular matrix, and blocks the proliferation of fibroblast.

The CAPACITY (clinical studies assessing pirfenidone in IPF: research of efficacy and safety outcome) Program was designed to confirm the effect of pirfenidone on lung function.3 In 2008, Japanese Ministry of Health, Labor, and Welfare approved use of pirfenidone for management of IPF and in 2011, European Commission approved its use for mild to moderate IPF.4 As measured by change in forced vital capacity (FVC), use of pifnidone has not been approved by FDA due to lack of efficacy and survival benefits5 and has demanded a Phase III clinical study ASCEND (NCT01366209) currently underway in USA. The most common side effect includes rash, photo sensitivity, dyspepsia, abdominal pain, nausea, anorexia, fatigue and lethargy, diarrhea, constipation, itching, dryness, and hyper pigmentation of the skin, headache, and weakness.

**N-acetyl cysteine (NAC)**

It is an anti-oxidant agent and precursor of glutathione. It restores depleted levels of glutathione, thus preventing lung injury from excessive production of oxidants. This theory is supported by low levels of glutathione in bronchoalveolar lavage fluid.

IPF International Group Exploring NAC I Annual Trial, in which azathioprine/NAC was compared to azathiprine/ prednisolone/placebo, has shown a lower rate of fall in vital capacity and single breath carbon monoxide diffusion capacity (DLCO) in favor of NAC group, thus helping the treatment.6 However, there is no significant difference in type or severity of adverse effect and mortality.

The multicenter PANTHER Trial (prednisolone, azathioprine and NAC: a study that evaluates response in IPF) has shown that triple therapy should not be used.7 However study is ongoing between mono therapy with NAC and placebo.

**Tyrosine kinase inhibitor**

Activation of various signaling pathway by several tyrosine kinase receptors in IPF has been shown to cause fibrosis. Inhibition of these receptors helps in slowing the progression of IPF.

Imatinib is a tyrosine kinase inhibitor that is being used in IPF. It acts against platelet derived growth factor receptor (PDGFRs) and has shown to have no effect on lung function and survival of the patient.8

**BIBF 1120 (Nintedanib)**

It is a potent inhibitor of vascular endothelial growth factor receptor, PDGFR, and basic fibroblast growth factor receptor. BBIF 1120 was used for treatment of IPF in Phase II trial to improve pulmonary fibrosis with BBIF 20 (8). BBIF 20 showed a significant effect on lung function decline compared to placebo. Total lung capacity was preserved, annual rate of lung function decline was reduced, and patient showing significant reduction in FVC were also less.

**Sildenafil (phoshodiesterase 5 inhibitor)**

Being a potent vasodilator, it increases the blood flow to a healthy part of the lung in patients with advanced IPF, thus improving gas exchange. Sildenafil was tested against placebo in sildenafil trial of exercise performance in IPF.9 There was improvement in dyspnea and quality-of-life especially in patient with right ventricular systolic dysfunction.

**Anticoagulation**

Use of anticoagulation on prophylactic and therapeutic basis has shown to ameliorate fibrosis. Efficacy of warfarin was tested in Anticoagulant Effectiveness in IPF Trial, which showed increased mortality. At present, nebulized heparin is under trial.

**Gastroesophageal reflux (GER) and microaspiration**

GER is an important risk factor to IPF and is found in 90% of patients with IPF. Use of antireflux medications has shown a decrease in fibrosis score on chest computed tomography. These medications are independent predictors of lower mortality.10

NON PHARMACOLOGICAL INTERVENTION

**Supportive care**

Supplemental oxygen, education of patient, pulmonary rehabilitation, and Streptococcus pneumoniae and Influenza vaccine are the most important supportive care. Pulmonary rehabilitation should be used as a treatment in the majority of patients as advised by ATS/ERS/JRS/ALAT official statement on IPF 2011.11

To get maximum physiological benefit, high intensity exercise, i.e., more than 60% maximum work rate should be done for at least 20 sessions 3 times a week.
**Stem cell therapy**

Autologous adipose stem cells are instilled into both lower lobes of the lung via the bronchoscope. No serious side effects and an improvement of FVC were observed in Phase I trial.12

**Lung transplant**

Lung transplant is most frequently done for IPF and is the second most common cause of transplant after chronic obstructive pulmonary disease. Transplant is done in patients with usual interstitial pneumonia and any of the following:13
- DLCO ≤39% of the predicted
- ≥10% decrement in FVC over last 6 months
- SpO₂ <88% during MWT
- HRCT shows honeycombing (fibrosis score >2).

**CONCLUSION**

Pirfenidone and NAC are the only effective pharmacotherapy available till date. Interim results of PANTHER Trial clearly indicate more risk with triple therapy. However, in Indian patients, trial of steroid therapy may be tried when there is doubt of chronic hypersensitivity pneumonitis. BIBF 1120 has also shown positive results in Phase II clinical trial and shows a positive response in deteriorating lung function.

**Funding:** No funding sources  
**Conflict of interest:** None declared  
**Ethical approval:** Not required

**REFERENCES**

1. Keane MP, Strieter RM, Lynch JP rd, Belperio JA. Inflammation and angiogenesis in fibrotic lung disease. Semin Respir Crit Care Med. 2006;27(6):589-99.
2. Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest. 2007;132(4):1311-21.
3. Noble PW, Albera C, Bradförd WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760-9.
4. Richeldi L, Yasothan U, Kirkpatrick P. Pirfenidone. Nat Rev Drug Discov. 2011;10(7):489-90.
5. Pulmonary-Allergy Drugs Advisory Committee Complete Response on Pirfenidone. Food and Drug Administration Centre for Drug Evaluation and Research, 2010. Available at http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pulmonary-allergydrugsadvisorycommittee/ucm208806.pdf. Accessed 16 Jun 2014.
6. Demedts M, Behr J, Buhl R, Costabel U, Dakhuljen R, Jansen HM, et al. High dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2012;366:1968-77.
7. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968-77.
8. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079-87.
9. Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363(7):620-8.
10. Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013;1(5):369-76.
11. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.
12. Tzouvelekis A, Koliakos G, Ntolios P, Baira I, Bouros E, Ōkonomou A, et al. Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal. J Transl Med. 2011;9:182.
13. Orens JB, Estenne M, Arcasoy S, Conte Jv, Corris P, Egan JJ, et al. International guidelines for the selection of lung transplant candidates: 2006 update – a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006;25(7):745-55.

doi: 10.5455/2319-2003.ijbcp20141012

Cite this article as: Acharya G, Arya S, Badal S, Kumar D, Samdariya S. Pharmacotherapy in idiopathic pulmonary fibrosis. Int J Basic Clin Pharmacol 2014;3:761-3.